Less Carcinogenic Chlorinated Estrogens Applicable to Hormone Replacement Therapy

Area of Science:

• Endocrinology
• Toxicology
• Medicinal Chemistry

Background:

• Human estrogens used in hormone replacement therapy (HRT) are recognized as potent carcinogens.
• There is a critical need for safer estrogen alternatives in HRT to mitigate cancer risks.

Purpose of the Study:

• To synthesize and evaluate the carcinogenic potential of novel chlorinated estrogens.
• To determine if chlorinated estrogens can serve as safer alternatives to conventional HRT estrogens while retaining therapeutic efficacy.

Main Methods:

• Synthesis of 2-chloro-17β-estradiol (2-ClE2), 4-chloro-17β-estradiol (4-ClE2), 2-chloro-17α-ethinylestradiol (2-ClEE2), and 4-chloro-17α-ethinylestradiol (4-ClEE2).
• Subcutaneous implantation of 2-ClE2 or 4-ClE2 in ACI rats for 52 weeks to assess mammary tumor induction.
• Oral administration of 2-ClEE2 or 4-ClEE2 to ovariectomized rats to evaluate uterotrophic potency and carcinogenicity.

Main Results:

• 17β-estradiol (E2) induced mammary tumors in rats, whereas 2-ClE2 and 4-ClE2 did not.
• The synthesized chlorinated estrogens (2-ClE2, 4-ClE2, 2-ClEE2, 4-ClEE2) did not induce tumors in the animal models.
• Chlorinated estrogens exhibited uterotrophic potency, indicating retained estrogenic activity, though slightly weaker than E2.
• Histological examination supported reduced carcinogenic effects of chlorinated estrogens.

Conclusions:

• Chlorination at the 2- or 4-position of estradiol may inhibit metabolic activation, thereby reducing carcinogenicity.
• Less carcinogenic chlorinated estrogens with preserved estrogenic potential represent promising safer alternatives for HRT.
• These findings suggest a potential for developing safer estrogen-based therapies for hormone replacement.